Formycon and Fresenius Kabi Canada receive Health Canada’s …
3 days ago · Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its commercialization partner Fresenius Kabi announce that Health Canada …
Formycon and Fresenius Kabi Canada receive Health Canada’s …
2 days ago · EQS-News: Formycon AG / Key word(s): Regulatory Approval Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), …
EQS-News: Formycon and Fresenius Kabi Canada receive Health …
2 days ago · EQS-News: Formycon AG / Key word(s): Regulatory Approval Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), …
Press Releases - Formycon AG
Formycon AG today announced that Hungary based specialty pharmaceutical company Gedeon Richter Plc. becomes strategic investor via cash capital increase from authorized capital in the …
Formycon and Fresenius Kabi Canada Receive Health Canada s …
2 days ago · Otulfi(R) Approved by Health Canada for Both Subcutaneous and Intravenous Formulations to Treat Serious Inflammatory Diseases Health Canada Joins the FDA and the …
EQS-News: Formycon included in TecDAX Index of Deutsche Börse
1 day ago · EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon included in TecDax Index of Deutsche Börse 09.01.2025 / 15:30 CET/CEST The issuer is solely …
EQS-News: Formycon reports nine-month results for 2024 and …
Nov 28, 2024 · Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) today reported on the financial results and business performance of the Formycon Group for the first …
Fresenius Kabi and Formycon Reach Settlement Agreement for …
Feb 2, 2023 · Fresenius Kabi and Formycon announced today that they have reached a settlement agreement with Johnson & Johnson for FYB202, a proposed ustekinumab …
Formycon reports successful first half of 2023
Aug 30, 2023 · Strong development of Biosimilar pipeline and good market establishment of FYB201 drive corporate success in the first half of 2023. The successful progress in the …
Fresenius Kabi & Formycon: Ustekinumab biosimilar deal
Feb 2, 2023 · Fresenius Kabi will commercialize Formycon’s Ustekinumab biosimilar candidate (FYB202) in key global markets after successful approval by respective health agencies. The …